Oakbrook Investments LLC lowered its position in shares of Celgene Co. (NASDAQ:CELG) by 13.9% in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 34,353 shares of the biopharmaceutical company’s stock after selling 5,525 shares during the quarter. Oakbrook Investments LLC’s holdings in Celgene were worth $5,009,000 as of its most recent SEC filing.
Other large investors also recently bought and sold shares of the company. Thompson Davis & CO. Inc. grew its position in Celgene by 5.9% in the second quarter. Thompson Davis & CO. Inc. now owns 773 shares of the biopharmaceutical company’s stock worth $100,000 after acquiring an additional 43 shares during the period. Arcadia Investment Management Corp MI grew its position in Celgene by 118.7% in the third quarter. Arcadia Investment Management Corp MI now owns 737 shares of the biopharmaceutical company’s stock worth $107,000 after acquiring an additional 400 shares during the period. Motco grew its position in Celgene by 19.3% in the second quarter. Motco now owns 981 shares of the biopharmaceutical company’s stock worth $127,000 after acquiring an additional 159 shares during the period. Penserra Capital Management LLC purchased a new position in Celgene in the second quarter worth approximately $129,000. Finally, Balentine LLC grew its position in Celgene by 83.5% in the second quarter. Balentine LLC now owns 1,057 shares of the biopharmaceutical company’s stock worth $137,000 after acquiring an additional 481 shares during the period. 79.74% of the stock is owned by hedge funds and other institutional investors.
CELG has been the subject of several analyst reports. Royal Bank of Canada lowered their price target on Celgene from $166.00 to $148.00 and set a “top pick” rating for the company in a research report on Friday, October 27th. Leerink Swann restated a “buy” rating and set a $156.00 price target on shares of Celgene in a research report on Friday, October 20th. Morgan Stanley lowered their price target on Celgene from $120.00 to $115.00 and set an “underweight” rating for the company in a research report on Monday, October 23rd. SunTrust Banks lowered their price target on Celgene from $156.00 to $127.00 and set a “buy” rating for the company in a research report on Friday, October 27th. Finally, William Blair restated an “outperform” rating on shares of Celgene in a research report on Friday, October 20th. One research analyst has rated the stock with a sell rating, fourteen have assigned a hold rating and nineteen have given a buy rating to the stock. The company presently has an average rating of “Buy” and an average target price of $131.18.
Celgene (NASDAQ:CELG) last issued its quarterly earnings results on Thursday, October 26th. The biopharmaceutical company reported $1.91 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $1.87 by $0.04. Celgene had a return on equity of 43.32% and a net margin of 30.06%. The firm had revenue of $3.29 billion for the quarter, compared to analysts’ expectations of $3.42 billion. During the same quarter in the previous year, the firm posted $1.58 EPS. The firm’s revenue for the quarter was up 10.2% on a year-over-year basis. equities research analysts forecast that Celgene Co. will post 6.68 earnings per share for the current fiscal year.
ILLEGAL ACTIVITY NOTICE: This piece of content was reported by StockNewsTimes and is the sole property of of StockNewsTimes. If you are viewing this piece of content on another site, it was copied illegally and reposted in violation of United States and international copyright law. The correct version of this piece of content can be read at https://stocknewstimes.com/2018/01/11/oakbrook-investments-llc-cuts-holdings-in-celgene-co-celg.html.
Celgene Corporation is an integrated global biopharmaceutical company. The Company, together with its subsidiaries, is engaged in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases through solutions in protein homeostasis, immuno-oncology, epigenetics, immunology and neuro-inflammation.
Receive News & Ratings for Celgene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celgene and related companies with MarketBeat.com's FREE daily email newsletter.